NCT02315612 2026-03-24
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
Clinical Trials
432 trialsNCT03939026 2026-03-02
ALPHA
Allogene Therapeutics
Phase 1 Completed
NCT02909777 2026-02-11
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03029338 2026-02-11
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Completed
NCT01625351 2026-02-06
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
Phase 1 Completed
NCT04022980 2025-12-30
Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma
Wake Forest University Health Sciences
Phase 1 Completed
NCT01695005 2025-12-26
A Study of LY3039478 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02211755 2025-11-28
Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02996773 2025-11-10
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
Phase 1 Completed
NCT03010176 2025-10-29
MK-1454-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02512497 2025-09-19
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT04169321 2025-08-22
Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors
Cytosite Biopharma Inc.
Phase 1 Completed
NCT04970992 2025-08-22
A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma
Da Zen Theranostics Inc
Phase 1 Completed
NCT03039114 2025-08-21
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Incyte Corporation
Phase 1 Completed
NCT03739931 2025-08-15
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
ModernaTX, Inc.
Phase 1 Completed
NCT01051635 2025-07-17
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03884556 2025-07-02
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Trishula Therapeutics, Inc.
Phase 1 Completed
NCT05290155 2025-06-06
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 1 Completed
NCT03448393 2025-06-04
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01877382 2025-03-27
A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas
Daiichi Sankyo
Phase 1 Completed
NCT06892119 2025-03-27
Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation
Hospital Universitario Dr. Jose E. Gonzalez
Phase 1 Completed
NCT01497184 2025-03-13
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01957735 2025-02-19
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
BPGbio
Phase 1 Completed
NCT03654716 2025-02-14
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01638533 2025-02-07
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT01703481 2025-02-03
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma
Janssen Research & Development, LLC
Phase 1 Completed
NCT05775406 2025-01-27
Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
Kymera Therapeutics, Inc.
Phase 1 Completed
NCT02323880 2025-01-14
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Children's Oncology Group
Phase 1 Completed
NCT00243087 2024-12-20
Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)
Boehringer Ingelheim
Phase 1 Completed
NCT02112526 2024-12-20
Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Acerta Pharma BV
Phase 1 Completed
NCT04136275 2024-12-12
CAR-37 T Cells in Hematologic Malignancies
Massachusetts General Hospital
Phase 1 Completed
NCT03030417 2024-12-10
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03524235 2024-11-12
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Cedars-Sinai Medical Center
Phase 1 Completed
NCT05567887 2024-11-06
A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies
Pfizer
Phase 1 Completed
NCT01359982 2024-11-01
DINAMIC
EpicentRx, Inc.
Phase 1 Completed
NCT02383368 2024-10-31
A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma
Astellas Pharma Inc
Phase 1 Completed
NCT02569476 2024-10-26
BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
BeiGene
Phase 1 Completed
NCT03323034 2024-10-22
Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Children's Oncology Group
Phase 1 Completed
NCT03936465 2024-10-02
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02594384 2024-08-22
LAM-002A/NHL
OrphAI Therapeutics
Phase 1 Completed
NCT04555811 2024-07-09
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT03934814 2024-07-01
Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
I-Mab Biopharma US Limited
Phase 1 Completed
NCT04231747 2024-05-20
A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Juno Therapeutics, a Subsidiary of Celgene
Phase 1 Completed
NCT04477772 2024-05-16
A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Completed
NCT01949883 2024-05-08
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
Constellation Pharmaceuticals
Phase 1 Completed
NCT00457782 2024-04-25
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
Kyowa Kirin Co., Ltd.
Phase 1 Completed
NCT04306224 2024-04-12
A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas
ImmuneOncia Therapeutics Inc.
Phase 1 Completed
NCT05602597 2024-03-06
HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI
Hutchmed
Phase 1 Completed
NCT05078593 2024-02-23
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma
Shanghai Henlius Biotech
Phase 1 Completed
NCT03964259 2024-02-13
Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia
Virginia Commonwealth University
Phase 1 Completed